Safety And Efficacy Of The Unique Opioid Buprenorphine For The Treatment Of Chronic Pain.

作者: Joseph V Pergolizzi Jr , Robert B Raffa

DOI: 10.2147/JPR.S231948

关键词:

摘要: Background Chronic pain is associated with decreased quality of life and one the most common reasons adults seek medical care, making treatment imperative for many aspects patient well-being. management typically involves use Schedule II full μ-opioid receptor agonists relief; however, increasing prevalence opioid addiction a national crisis that impacting public health social economic welfare. Buprenorphine III partial agonist an equally effective but potentially safer option chronic than agonists. The purpose this review to provide overview clinical efficacy safety transdermal buccal formulations buprenorphine, which are approved by Food Drug Administration pain, compared extended-release Methods Controlled or randomized controlled trial information was retrieved from EMBASE, Medline, PubMed using search terms "buprenorphine" AND "chronic" "pain." Results A total 33 studies were ultimately used in review, including 29 (88%) on buprenorphine 4 (12%) film. Although measure intensity varied among studies, each these trials demonstrated relief. 28 also assessed safety, concluding generally well tolerated. Conclusion Comparison current data along results responder analyses support over preferential pain; head-to-head warranted.

参考文章(89)
Rudolf Likar, Transdermal buprenorphine in the management of persistent pain - safety aspects. Therapeutics and Clinical Risk Management. ,vol. 2, pp. 115- 125 ,(2006)
Richard L. Rauck, Srinivas Nalamachu, James E. Wild, George S. Walker, Cynthia Y. Robinson, Charles S. Davis, Stephen J. Farr, Single‐Entity Hydrocodone Extended‐Release Capsules in Opioid‐Tolerant Subjects with Moderate‐to‐Severe Chronic Low Back Pain: A Randomized Double‐Blind, Placebo‐Controlled Study Pain Medicine. ,vol. 15, pp. 975- 985 ,(2014) , 10.1111/PME.12377
Nancy D. Campbell, Anne M. Lovell, The history of the development of buprenorphine as an addiction therapeutic Annals of the New York Academy of Sciences. ,vol. 1248, pp. 124- 139 ,(2012) , 10.1111/J.1749-6632.2011.06352.X
David P. Kao, Mark C. P. Haigney, Philip S. Mehler, Mori J. Krantz, Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration Addiction. ,vol. 110, pp. 1468- 1475 ,(2015) , 10.1111/ADD.13013
Aaron Yarlas, Kate Miller, Warren Wen, Shau Yu Lynch, Catherine Munera, Joseph V. Pergolizzi, Robert Raffa, Steven R. Ripa, Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain Postgraduate Medicine. ,vol. 127, pp. 38- 45 ,(2015) , 10.1080/00325481.2014.992715
Joseph Pergolizzi, Anna Maria Aloisi, Albert Dahan, Joerg Filitz, Richard Langford, Rudolf Likar, Sebastiano Mercadante, Bart Morlion, Robert B. Raffa, Rainer Sabatowski, Paola Sacerdote, Luis M. Torres, Avi A. Weinbroum, Current knowledge of buprenorphine and its unique pharmacological profile. Pain Practice. ,vol. 10, pp. 428- 450 ,(2010) , 10.1111/J.1533-2500.2010.00378.X
Warren Wen, Shau Yu Lynch, Catherine Munera, Ruth Swanton, Steven R Ripa, Howard Maibach, Application site adverse events associated with the buprenorphine transdermal system: a pooled analysis. Expert Opinion on Drug Safety. ,vol. 12, pp. 309- 319 ,(2013) , 10.1517/14740338.2013.780025
John Mendelson, Robert A. Upton, E. Thomas Everhart, Peyton Jacob III, Reese T. Jones, Bioavailability of Sublingual Buprenorphine The Journal of Clinical Pharmacology. ,vol. 37, pp. 31- 37 ,(1997) , 10.1177/009127009703700106